Name: Dersimelagon (MT-7117) in Erythropoietic protoporphyria or X-linked protoporphyria: Dosage
Published: 2026-09-21T21:42:40-04:00

Product information and disease description Product description Product information Dosing and administration

Dosage

4 evidence topics · 5 sources

Dose studied in the phase 3 trial

“Participants were randomly assigned to either a placebo group or an active treatment group (dersimelagon 200 mg once daily) for a 16-week double-blind period, followed by a 36-week open-label extension period of active treatment.” (opens the source at this quote in a new tab)

“After screening, study participants (ranging from 12 to 75 years of age) received either dersimelagon 200 mg or placebo once daily.” (opens the source at this quote in a new tab)

Doses studied in the phase 2 trial

“Patients 18 to 75 years of age were randomly assigned in a 1:1:1 ratio to receive placebo or dersimelagon at a dose of 100 or 300 mg once daily for 16 weeks.” (opens the source at this quote in a new tab)

Doses carried into late-stage evaluation

“dersimelagon 100 and 200 mg (doses currently being evaluated for the treatment of erythropoietic protoporphyria and X‐linked protoporphyria)” (opens the source at this quote in a new tab)

Dose used in the long-term extension study

“Dersimelagon 200mg” (opens the source at this quote in a new tab)